FDA Announces Label Changes for Darunavir (Prezista), Didanosine (Videx), and Lopinavir/ritonavir (Kaletra)
2-02-2010

Raltegravir (Isentress) Activity Is Durable at 96 Weeks; Switch from Lopinavir/ritonavir Results in More Viral Breakthrough but Better Lipid Profiles
1-26-2010

Tenofovir/emtricitabine (Truvada) plus Lopinavir/ritonavir (Kaletra) or Raltegravir (Isentress) Work Well for Post-exposure Prophylaxis
9-11-2009

At 96 Weeks, Epzicom and Truvada Demonstrate Comparable Efficacy, Safety, and Tolerability when Combined with Lopinavir/ritonavir (Kaletra)
8-4-2009

Once-daily Lopinavir/ritonavir (Kaletra) Works as Well as Twice-daily dosing in Treatment-naive HIV Patients
7-31-2009

Switching from Lopinavir/ritonavir (Kaletra) to Boosted Atazanavir (Reyataz) Reduces Visceral Fat and Improves Glucose Metabolism
7-10-2009

Protease Inhibitor Monotherapy using Lopinavir/ritonavir (Kaletra) or Boosted Atazanavir (Reyataz) Maintains Viral Suppression
6-19-2009

How Effective Are Boosted Dual Protease Inhibitor Regimens with No Additional Drugs in Treatment-naive HIV Patients?
5/22/09

First-line Therapy with Zidovudine/lamivudine plus Lopinavir/ritonavir Leads to Greater Bone Loss than Nevirapine plus Lopinavir/ritonavir
5/19/09

Lopinavir/ritonavir (Kaletra) Is Superior to Nevirapine (Viramune) for HIV-infected Children Who Received Single-dose Nevirapine at Birth
5/15/09

Raltegravir (Isentress) plus Lopinavir/ritonavir (Kaletra) Produces Rapid Viral Load Decline in Treatment-naive HIV Patients
5/08/09

Raltegravir (Isentress) plus Lopinavir/ritonavir (Kaletra) Produces More Rapid HIV Decline in Treatment-naive HIV Patients
4/10/09

Lopinavir/ritonavir (Kaletra) Label Changed to Reflect Potential Risk of Heart Rhythm Abnormalities
4/10/09

Lopinavir/ritonavir (Kaletra) Monotherapy May Be Hazardous for Patients with a History of Low CD4 Cell Counts
3/03/09

Switching from Lopinavir/ritonavir (Kaletra) to Raltegravir (Isentress) Leads to Poorer HIV Suppression, but Better Lipid Profiles: SWITCHMRK
2/17/09

Factors affecting virologic response to darunavir/ritonavir and lopinavir/ritonavir in treatment-naïve HIV-1-infected patients in ARTEMIS at 96 weeks
2/17/09

Single Agent Therapy with Lopinavir/Ritonavir Suppresses HIV-1 Viral Replication in ARV Naïve Patients: IMANI II - 96 Week Final Results - 11/05/2008

Three-year Efficacy of Lopinavir/ritonavir Monotherapy in the OK04 Trial - 11/05/2008

Time to Virological Failure with Boosted Atazanavir (Reyataz) or Lopinavir/ritonavir (Kaletra) Is Not Affected by Use of H2 Receptor Blockers - 9/12/2008

Effect of Lopinavir/ritonavir (Kaletra) Monotherapy on Symptoms and Quality of Life - 9/12/2008

No Increased Risk of Birth Defects with Prenatal Lopinavir/ritonavir (Kaletra) Exposure - 8/22/08

Time to Virological Failure with Boosted Atazanavir (Reyataz) or Lopinavir/ritonavir (Kaletra) Is Not Affected by Use of H2 Receptor Blockers - 9/12/2008

Boosted Atazanavir and Lopinavir/ritonavir (Kaletra) Have Similar Efficacy, but Side Effects Differ across Racial/ethnic Groups - 8/12/08

Lopinavir/ritonavir (Kaletra) Tablet Dosed Once-Daily or Twice-Daily Confers Similar Clinical Results across Racial/ethnic Lines - 8/12/08

Trough Lopinavir Concentrations <1 ƒÊg/mL Are Not Associated with Virologic Failure in Antiretroviral-Naive Patients Receiving a Lopinavir/ritonavir-Based 3-Drug Regimen - 8/10/08

Impact of Gender on Response to Lopinavir/ritonavir (LPV/r) Tablets Dosed QD or BID Administered with Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) in Antiretroviral-naïve (ARV) Subjects: Results from Study M05-730 - 8/10/08

Comparable HIV-1 Viral Suppression and Immunologic Recovery of White and Non-White Antiretroviral-Naïve Subjects Taking Lopinavir/ritonavir (LPV/r) Tablets + Tenofovir Disoproxil Fumarate (TDF) and Emtricitabine (FTC) through 48 Weeks - 8/10/08

Week-96 End of Trial Analysis of Antiretroviral-naïve Patients Randomized to the Lopinavir/ritonavir Single Drug Arm in the MONARK Trial - 8/10/08

Predictors of Persistence with Lopinavir/ritonavir (LPV/r) Soft-Gelatin Capsule-Based Antiretroviral Regimens - 8/10/08

Health-Related Quality of Life (HRQoL) Improvement in Antiretroviral (ARV) Naïve HIV-infected Patients on Atazanavir or Lopinavir With Ritonavir Regimens: Week 24 Results From the CASTLE Study - 8/10/08

Efficacy and Safety By Racial Group in ARV-Naïve Subjects Treated With Atazanavir/Ritonavir or Lopinavir/Ritonavir: 48-Week Results for the CASTLE Study (AI424138) - 8/10/08

Health-Related Quality of Life (HRQoL) Improvement in Antiretroviral (ARV) Naïve HIV-infected Patients on Atazanavir or Lopinavir with Ritonavir Regimens: Week 24 Results From the CASTLE Study - 8/10/08

Epzicom QD vs Truvada QD, Both with Kaletra QD, in ART-Naïve Patients: The HEAT Study 96 Weeks Analysis Results - 8/10/08

Similarity in Efficacy and Safety of Abacavir/Lamivudine (ABC/3TC) Compared to Tenofovir/Emtricitabine (TDF/FTC) in Combination with QD Lopinavir/Ritonavir (LPV/r) Over 96 Weeks in the HEAT Study - 8/10/08

Boosted Atazanavir and Lopinavir/ritonavir (Kaletra) Have Similar Efficacy, but Side Effects Differ across Racial/ethnic Groups - 8/12/08

Lopinavir/ritonavir (Kaletra) Tablet Dosed Once-Daily or Twice-Daily Confers Similar Clinical Results across Racial/ethnic Lines - 8/12/08

Efficacy and Safety of Once-daily Boosted Darunavir (Prezista) versus Lopinavir/ritonavir (Kaletra) in Treatment-naive HIV Patients: ARTEMIS Trial - 7/15/08

Double-boosted Protease Inhibitors Saquinavir (Invirase) and Lopinavir/ritonavir (Kaletra) Produce Significant CD4 Rise and Viral Load Decline in Treatment-experienced Children - 6/10/08

Lower-Strength Lopinavir/Ritonavir (Kaletra, Aluvia) Tablet Approved in Europe for Children with HIV  - 4/11/08

Is There a Potential Role for Ritonavir-boosted Protease Inhibitor Monotherapy? - 4/01/08

Once-daily Lopinavir/ritonavir (Kaletra) and Nevirapine (Viramune) Appear as Effective as Twice-daily - 2/22/08

Double Protease Inhibitor Therapy with Lopinavir/ritonavir (Kaletra) plus Atazanavir (Reyataz) in Treatment-naive Patients: LORAN Study - 2/15/08

Bone Mineral Density (BMD) 96 Weeks after Antiretroviral Therapy (ART) Initiation: A Randomized Trial Comparing Efavirenz (EFV)-Based Therapy to a Lopinavir/ ritonavir (LPV/r)-Containing Regimen with Simplification to LPV/r Monotherapy.   - 2/10/08

Study M05-730 Primary Efficacy Results at Week 48: Phase 3, Randomized, Open-Label Study of Lopinavir/ritonavir (LPV/r) Tablets Once Daily (QD) versus Twice Daily (BID), Co-Administered with Tenofovir DF (TDF) + Emtricitabine (FTC) in Antiretroviral-Naïve (ARV) HIV-1 Infected Subjects.   - 2/10/08

Prevalence, Mutational Patterns and Phenotypic Correlates of the L76V Protease Mutation in Relation to LPV Associated Mutations.   - 2/10/08